Skip to main content
Equibles
PRLD logo

PRLD · Prelude Therapeutics Inc

Track PRLD — free

Use PRLD with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about PRLD

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$6.63 +0.13 (+2.00%) At close · Aug 21
Market Cap
$529.10M
Shares
79.80M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$6.63 Open$6.56 Day$6.40–6.82 52W close$0.99–6.63 Avg vol 30d452K Short int3.7M · 4.6% float · 9.3d Short vol37% Last earningsMar 10, 2026 DataSep 2020–Aug 2026 Filing10-Q · Aug 11

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 11, 2026

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 15.1 · calm Equity put/call 0.58
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +95%
above
Price vs 50-day avg +40%
above
RSI (14) 75
overbought
MACD trend Positive
52-week position 100%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +73%
trailing
6-month return +145%
trailing
YTD return +129%
this year
Relative strength +133%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $5 › 200d $3 — 50d above 200d
Institutional flow Accumulating
+40% holders QoQ · +34 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
4.60% of float · ▲ +11.7% MoM · 9.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
77 holders — near 3-yr high, broad support
Squeeze score 85
high risk · 0–100
Fundamentals
Strong
Revenue growth +73%
Y/Y
EPS growth +23%
Y/Y
Free cash flow $-56.4M
Balance sheet $35.3M
net cash
Quant / Vol
risk profile
Very High
Volatility 200%
annualized · 1-yr
Max drawdown −70%
past year
ATR 6.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
1 · 2 · 4
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+95% Bullish
Price vs 50-day avg
+40% Bullish
RSI (14)
75 Bearish
MACD trend
Positive Bullish
52-week position
100% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $5 › 200d $3 — 50d above 200d
Institutional flow Accumulating
+40% holders QoQ · +34 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
4.60% of float · ▲ +11.7% MoM · 9.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
77 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $7 · 100% Range high $7
vs 200-day avg +95% vs 50-day avg +40%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash, cash equivalents, restricted cash and marketable securities $84.8M three months ended March 31, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
PRLD
Prelude Therapeutics Inc
this stock
$529.10M +128.6% +73.4% — 4.6%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $136.93B +20.9% +46.2% 31.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $85.87B +8.1% +20.8% 20.7 3.3%
ARGX
Argenx SE
 $64.56B +23.6% — — 2.1%
CSLLY
Csl Ltd
 $58.31B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
77
% held
62.5%
Net QoQ
+19.1M sh
Top holder
ORBIMED ADVISORS LLC
Held Float
View
Held by Funds
Fund positions
27
View
Short & Settlement
Short Interest Rising
Shares short
3.7M
Days to cover
9.3d
Change
+383.7K sh
View
Short Volume
Short vol %
37%
As of
Aug 21, 2026
Short Total
View
Fails to Deliver
FTD shares
9.9K
Value
$46.0K
As of
Jul 29, 2026
View
Off-Exchange
Off-exchange %
36.2%
Week of
Jul 13, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$12.1M
Net income (FY)
$-99.5M
EPS diluted
$-1.29
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 11, 2026
This year
16
View
Exempt Offerings
Offering
$50.0M
Filed
Aug 28, 2020
View
Earnings & Events
Earnings Calls
Last call
Jun 10, 2026
View

Performance

5D 20D 120D MTD YTD
PRLD +19.5% +73.1% +144.7% +44.1% +128.6%
SPY -1.4% +3.6% +11.6% +2.5% +12.3%
vs SPY +20.8% +69.5% +133.1% +41.6% +116.3%
Key facts CIK 1678660 CUSIP 74065P101 13F (30d) 76 filings 76 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)